Dr. Swaminath is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
161 Fort Washington Ave
Ste 862
New York, NY 10032Phone+1 212-305-1021Fax+1 212-305-5576
Summary
- Dr. Arun Swaminath is a gastroenterologist in New York, NY and is chief of gastroenterology at Lenox Hill Hospital. He received his medical degree from University of California San Diego School of Medicine and has been in practice 17 years. He is experienced in inflammatory bowel disease, ulcerative colitis, and crohn's disease.
Education & Training
- Icahn School of Medicine at Mount SinaiPost-Doctoral Fellowship, 2007 - 2008
- University of California (San Diego) Medical CenterFellowship, Gastroenterology, 2004 - 2007
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2000 - 2003
- University of California San Diego School of MedicineClass of 2000
Certifications & Licensure
- CA State Medical License 2001 - Present
- NY State Medical License 2007 - 2026
- American Board of Internal Medicine Gastroenterology
Clinical Trials
- Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) Start of enrollment: 2017 Sep 15
Roles: Principal Investigator
- A Study of CDPATH™ to Help Manage and Treat Crohn's Disease Start of enrollment: 2021 Jun 25
Roles: Principal Investigator
Publications & Presentations
PubMed
- 56 citationsRetrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.Joseph Meserve, Satimai Aniwan, Jenna L. Koliani-Pace, Preeti Shashi, A Weiss
Clinical Gastroenterology and Hepatology. 2019-07-01 - 53 citationsVedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.Neeraj Narula, Farhad Peerani, Joseph Meserve, Gursimran Kochhar, Khadija Chaudrey
The American Journal of Gastroenterology. 2018-09-01 - 43 citationsComparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.Matthew Bohm, Ronghui Xu, Yiran Zhang, Sashidhar Varma, Monika Fischer
Alimentary Pharmacology & Therapeutics. 2020-08-01
Journal Articles
- Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumLeah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
- Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumGursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature
Press Mentions
- Colon Cancer 'Epidemic That Has Been Underneath the Surface for a Long Time': Physicians at Seminar in New YorkMarch 20th, 2023
- MNT Investigates: Can 'Good' Bacteria Treat Crohn's Disease?June 7th, 2022
- Q&A: Patients with Crohn’s Disease May Prefer Mediterranean DietJune 28th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: